News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018